News | September 17, 2012

TCT 2012 Late-Breaking Trials, First Report Investigations Announced

Clinical trial findings feature research breakthroughs in interventional cardiology


September 17, 2012 — The Cardiovascular Research Foundation (CRF) announced the late-breaking trials and first report investigations that will be presented at next month's Transcatheter Cardiovascular Therapeutics (TCT) 2012 scientific symposium. TCT, the world's premier educational meeting specializing in interventional cardiovascular medicine, will take place Oct. 22-26 in Miami, Fla.

The studies selected will shed new light on the effectiveness and safety of minimally invasive techniques, pharmaceuticals, technologies and devices that show potential to treat or prevent cardiovascular disease, one of the global leading causes of death. Late-breaking clinical trials and first report investigations will be presented in the Main Arena and highlighted during press conferences scheduled for Wednesday, Thursday and Friday (Oct. 24-26).


Wednesday, Oct. 24, 2012

Late-Breaking Trials (11:20 a.m. — 12:20 p.m.)

  • FAME 2 Cost-effectiveness: A Prospective, Randomized Trial Evaluating the Cost-effectiveness of FFR-Guided PCI in Patients with Stable Coronary Artery Disease. It will be presented by William F. Fearon.
     
  • MASTER: A Prospective, Randomized Trial of a PET Micronet Mesh-Covered Stent vs. Standard Stents in Patients with ST-Segment Elevation Myocardial Infarction. It will be presented by Gregg W. Stone.
     
  • ISAR-LEFT MAIN 2: A Prospective, Randomized Trial of Everolimus-Eluting vs. Zotarolimus-Eluting Stents in Patients with Unprotected Left Main Disease. The session will be presented by Julinda Mehilli.


First Report Investigations (12:20 — 1:05 p.m.)

  • PARTNER Cohort B Three Year: Clinical and Echocardiographic Outcomes from a Prospective, Randomized Trial of Transcatheter Aortic Valve Replacement in "Inoperable" Patients. The session will be presented by Samir R. Kapadia.
     
  • TRILOGY ACS Angiographic Cohort: A Prospective, Randomized Trial of Prasugrel vs. Clopidogrel in Patients with Non-ST-Segment Elevation ACS Who Are Medically Managed After Coronary Angiography. The session will be presented by Stephen D. Wiviott.
     
  • A Prospective, Randomized Trial of Nitinol Stents vs. Balloon Angioplasty in Obstructive Popliteal Lesions. The session will be presented by Thomas Zeller.



Thursday, Oct. 25, 2012

Late-Breaking Trials (11:15 a.m. — 12:15 p.m.)

  • RESPECT: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Stroke. The session will be presented by John D. Carroll.
     
  • The PC Trial: A Prospective, Randomized Trial of PFO Closure vs. Medical Therapy in Patients with Cryptogenic Embolism. The session will be presented by Bernhard Meier.
     
  • A Prospective, Randomized Trial of Sliding-Scale Hydration for Prevention of Contrast Nephropathy. The session will be presented by Somjot S. Brar.


First Report Investigations (12:15 p.m. — 1 p.m.) 

  • ADAPT-DES One Year: A Large-Scale, Multicenter, Prospective, Observational Study of the Impact of Clopidogrel Hyporesponsiveness on Patient Outcomes. The session will be presented by Gregg W. Stone.
     
  • AIDA STEMI MRI: Cardiac MRI Substudy from a Prospective, Randomized Trial of Intracoronary Abciximab in Patients with ST-Segment Elevation Myocardial Infarction. The session will be presented by Holger Thiele.
     
  • A Prospective, Randomized Trial of Post-Conditioning in Patients with ST-Segment Elevation Myocardial Infarction. The session will be presented by Joo-Yong Hahn.



Friday, Oct. 26, 2012

Late-Breaking Trials (11:15 a.m. — 12:15 p.m.)

  • XIMA: A Prospective, Randomized Trial of Everolimus-Eluting Stents vs. Bare-Metal Stents in Octogenarians. The session will be presented by Adam J. de Belder.
     
  • ISAR-DESIRE 3: A Prospective, Randomized Trial of Paclitaxel-Eluting Balloons vs. Paclitaxel-Eluting Stents vs. Balloon Angioplasty for Restenosis of "Limus"-Eluting Coronary Stents. The session will be presented by Robert A. Byrne.
     
  • STEMI-RADIAL: A Prospective, Randomized Trial of Radial vs. Femoral Access in Patients with ST-Segment Elevation Myocardial Infarction. The session will be presented by Ivo Bernat.


To view the complete TCT agenda, visit: www.tctconference.com/agenda.html


Related Content

News | Cardiovascular Clinical Studies

Nov. 18, 2024 — Silence Therapeutics presented end-of-treatment data from its Phase 2 ALPACAR-360 study of zerlasiran, a ...

Home November 18, 2024
Home
News | Cardiovascular Clinical Studies

Aug. 15, 2024 — According to a new study being presented at ACC Asia 2024 in Delhi, India, drinking over 400 mg of ...

Home August 14, 2024
Home
Videos | Cardiovascular Clinical Studies

As part of DAIC's continuing Thought Leadership Series, this month Editorial Director Melinda Taschetta-Millane sits ...

Home July 30, 2024
Home
News | Cardiovascular Clinical Studies

July 25, 2024 — BioCardia, Inc., a global leader in cellular and cell-derived therapeutics for the treatment of ...

Home July 25, 2024
Home
News | Cardiovascular Clinical Studies

July 18, 2024 — Elucid, a pioneering AI medical technology company providing physicians with imaging analysis software ...

Home July 18, 2024
Home
News | Cardiovascular Clinical Studies

July 10, 2024 — CellProthera, a private company specializing in cell-based therapies for repairing ischemic tissues, and ...

Home July 10, 2024
Home
News | Cardiovascular Clinical Studies

July 9, 2024 — Microbot Medical Inc. announced the completion of the first procedure in a patient utilizing its LIBERTY ...

Home July 09, 2024
Home
News | Cardiovascular Clinical Studies

June 26, 2024 — Semaglutide, a medication initially developed for type 2 diabetes and obesity, significantly improves ...

Home June 26, 2024
Home
News | Cardiovascular Clinical Studies

June 21, 2024 — Lexicon Pharmaceuticals, Inc. announced that the peer-reviewed Journal of the American College of ...

Home June 21, 2024
Home
News | Cardiovascular Clinical Studies

June 20, 2024 — Microbot Medical Inc. announced its agreement with Brigham and Women’s Hospital (BWH), a leading ...

Home June 20, 2024
Home
Subscribe Now